We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Prediction of Drug Interactions With CYP2C9 Substrates

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00226538
Recruitment Status : Completed
First Posted : September 27, 2005
Last Update Posted : October 29, 2008
Information provided by:

September 12, 2005
September 27, 2005
October 29, 2008
August 1999
Not Provided
Phenytoin metabolic ratio prior to and following exposure to fluconazole, diclophenac and rifampicin.
Same as current
Complete list of historical versions of study NCT00226538 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Prediction of Drug Interactions With CYP2C9 Substrates
Prediction of Potential Drug Interaction With CYP2C9 Substrate by Using Phenytoin Metabolic Ratio as a Marker of Its Activity in-Vivo.

CYP2C9, is one of the major drug metabolism enzymes accounting for about 20% of the hepatic cytochrome P450 content and being second only to CYP3A4.

The proposed study will explore different possible drug interactions with CYP2C9 substrates by evaluating the effect of prototype inducers and inhibitors on the phenotypic trait measurement. It is expected that the identification of drugs that might interact with CYP2C9 substrates will be used to rationalize future drug interaction studies designed to evaluate the actual magnitude of effect and its clinical implications. This approach should be particularly useful when applied to those CYP2C9 drugs characterized by a narrow therapeutic index (i.e. warfarin).

This study will consist of three study periods separated from each other by a two weeks washout period. In the course of the study the subjects will receive in a double blind, crossover fashion, rifampin 300 mg. twice daily, diclofenac 50 mg twice daily. and fluconazole 200 mg. twice daily, each for one week. All drugs will be administered as identical looking tablets that will be prepared at the pharmacy of the Hadassah University Hospital and their order of administration will be randomized.On the day prior to, on day 6 of and 7 days following each drug period, the activity of CYP2C9 will be evaluated by the administration of a single phenytoin 300 mg. dose. The subjects will be requested to collect their urine for 24 hours and a single blood sample will be obtained 12 hours post phenytoin intake.

Not Provided
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Healthy Volunteers
  • Drug: Phenytoin
  • Drug: Rifampicin
  • Drug: Diclophenac
  • Drug: Fluconazole
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
Not Provided

Inclusion Criteria:

  • Age range 20-50
  • Absence of significant disease states

Exclusion Criteria:

  • Known hypersensitivity to one of the drugs used in the study
  • Significant disease states
  • Regular use of drugs (including birth control pills)
Sexes Eligible for Study: All
20 Years to 50 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
Hadassah Medical Organization
Not Provided
Principal Investigator: Yoseph Caraco, MD Hadassah Medical Organization
Hadassah Medical Organization
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP